.jpg "C. Andrew Basham, PhD photo")
Research Fellow
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital / Harvard Medical School, Boston MA
Dr. C Andrew Basham PhD, is a Research Fellow in the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, where he conducts research on prescription opioid utilization, clinical drug-drug interaction signal detection, applying causal inference methods for comparative safety research. He is leading an investigation into missing race and ethnicity data in a funded project working towards pharmacoequity and serves as Pharmacoecuity Research Resources Subgroup Lead in the Divion's DEI Initiative. As a long-term program of research, he is developing a survivorship lens for causal inference in post-critical illness outcomes and care with a focus in long-term HIV survivor health outcomes and pharmaceutical drug treatment.
In 2017-2021, under the supervision of Drs. Ehsan Karim and James Johnston, Andrew completed his doctoral research on TB survivor health using causal inference methods with health administrative data in British Columbia, Canada. Methods used included high-dimensional propensity scoring, with hybrid machine learning, directed acyclic graphs (DAGs), E-values for unmeasured confounding, and causal mediation analysis of the effect of TB diagnosis on depression risk as mediated by length of stay in hospital. Andrew has published extensively during his PhD and is developing an area of “survivorship epidemiology” where diseases and their diagnosis/treatment are the exposures of interest and survivor-important outcomes are studied.
At the beginning of his professional career, Andrew moved to northern Manitoba, where he worked in remote Indigenous communities as a health policy analyst for the Manitoba Keewatinowi Okimakanak. There he developed an interest tuberculosis prevention, diagnosis, and care, as well as public health policy and research generally. In his MSc thesis, Andrew investigated differences in TB program performance between First Nations (on and off-reserve), immigrants, and Canadian-born non-First Nations, using real-world surveillance data, which lead to a life-long interest in epidemiological research to improve health for all.
